Clinical trial of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in painful osteoarticular conditions.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D004231:Diuresis / Q000187:drug effects; D005260:Female; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D010653:Phenylbutazone / Q000627:therapeutic use; D010919:Placebos; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D013729:Terpenes / Q000009:adverse effects / Q000627:therapeutic use*; D000637:Transaminases / Q000097:blood; D014527:Uric Acid / Q000097:blood
D000893:Anti-Inflammatory Agents; D010919:Placebos; D011720:Pyrazoles; D013729:Terpenes; D014527:Uric Acid; D000637:Transaminases; D010653:Phenylbutazone